

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Mel JuSo

RRID:CVCL_1403

Type: Cell Line

Proper Citation

RRID:CVCL_1403

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1403

Proper Citation: RRID:CVCL_1403

Description: Cell line Mel JuSo is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Cutaneous melanoma

Defining Citation: [PMID:2174414](#), [PMID:6895502](#), [PMID:9598804](#), [PMID:10766161](#), [PMID:11668190](#), [PMID:15009714](#), [PMID:18698037](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Mel JuSo

Synonyms: MEL-Juso, MEL-JUSO, Mel-Juso, Mel Juso, MelJuSo, MELJUSO, JuSo

Cross References: BTO:BTO_0001588, CLO:CLO_0007676, EFO:EFO_0022434, EFO:EFO_0022720, CLDB:cl3440, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:548, BioSample:SAMN03471884, BioSample:SAMN10988249, cancercellines:CVCL_1403, Cell_Model_Passport:SIDM00336, ChEMBL-Cells:ChEMBL3308761, ChEMBL-Targets:ChEMBL1075501, CLS:300282, Cosmic:706091, Cosmic:888060, Cosmic:888835, Cosmic:897474, Cosmic:908125, Cosmic:1020272, Cosmic:1022285,

Cosmic:1459306, Cosmic:1995505, Cosmic-CLP:908125, DepMap:ACH-000881, DSMZ:ACC-74, DSMZCellDive:ACC-74, EGA:EGAS00001000978, GDSC:908125, GEO:GSM887309, GEO:GSM888385, GEO:GSM1374670, GEO:GSM1670095, IARC_TP53:21493, LiGeA:CCL_674, LINCS_LDP:LCL-1252, PharmacDB:MELJUSO_915_2019, PRIDE:PXD011899, PRIDE:PXD019519, PRIDE:PXD021877, PRIDE:PXD030304, Progenetix:CVCL_1403, PubChem_Cell_line:CVCL_1403, Wikidata:Q54905064

ID: CVCL_1403

Record Creation Time: 20220427T220801+0000

Record Last Update: 20260829T234614+0000

Ratings and Alerts

No rating or validation information has been found for Mel JuSo.

No alerts have been found for Mel JuSo.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lörentz S, et al. (2026) SNAT1 (SLC38A1) Is Not the Main Glutamine Transporter in Melanoma, but Controls Metabolism via Glutamine-Dependent Activation of P62 (SQSTM1)/cMYC-Axis. *Cancers*, 18(7).

Gierisch ME, et al. (2026) Mitochondria serve as a holdout compartment for aggregation-prone proteins hindering efficient degradation. *Nature communications*, 17(1).

Chancellor A, et al. (2025) The carbonyl nucleobase adduct M3Ad is a potent antigen for adaptive polyclonal MR1-restricted T cells. *Immunity*, 58(2), 431.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF? complex for genomic stability. *Cell reports*, 44(11), 116495.

Prota G, et al. (2025) Mitochondria regulate MR1 protein expression and produce self-metabolites that activate MR1-restricted T cells. *Proceedings of the National Academy of Sciences of the United States of America*, 122(20), e2418525122.

Tröster BC, et al. (2025) Emerging role of ARHGAP29 in melanoma cell phenotype switching. *Molecular oncology*.

Saamarthy K, et al. (2025) An optimised Bcl-3 inhibitor for melanoma treatment. *British journal of pharmacology*, 182(11), 2426.

Blundell SV, et al. (2025) Mammalian and bacterial adaptors function as co-disinhibitory pairs to activate the E3 ubiquitin ligase WWP2. *The Journal of biological chemistry*, 301(12), 110847.

Schoufour TAW, et al. (2024) CRISPR-Cas9 screening reveals a distinct class of MHC-I binders with precise HLA-peptide recognition. *iScience*, 27(6), 110120.

Devitt L, et al. (2024) NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma. *Cell communication and signaling : CCS*, 22(1), 256.

Qiao X, et al. (2024) Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. *Molecular cancer*, 23(1), 120.

Jongsma MLM, et al. (2024) Systems mapping of bidirectional endosomal transport through the crowded cell. *Current biology : CB*, 34(19), 4476.

Meißgeier T, et al. (2024) Splicing control by PHF5A is crucial for melanoma cell survival. *Cell proliferation*, e13741.

van Vliet AA, et al. (2023) Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. *iScience*, 26(7), 107078.

Díaz-Anaya AM, et al. (2023) The ? Isoform of Human ATP-Binding Cassette B5 Transporter, ABCB5?, Localizes to the Endoplasmic Reticulum. *International journal of molecular sciences*, 24(21).

Martín-Vega A, et al. (2023) Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species. *Science advances*, 9(7), eadd7969.

Zimmermann T, et al. (2023) Cold Atmospheric Plasma Triggers Apoptosis via the Unfolded Protein Response in Melanoma Cells. *Cancers*, 15(4).

Xu S, et al. (2023) Cytosolic stress granules relieve the ubiquitin-proteasome system in the nuclear compartment. *The EMBO journal*, 42(3), e111802.

Linck-Paulus L, et al. (2022) A previously unknown Argonaute 2 variant positively modulates the viability of melanoma cells. *Cellular and molecular life sciences : CMLS*, 79(9), 475.

Linck-Paulus L, et al. (2021) Learning from Embryogenesis-A Comparative Expression Analysis in Melanoblast Differentiation and Tumorigenesis Reveals miRNAs Driving Melanoma Development. *Journal of clinical medicine*, 10(11).